{"name":"Pharvaris","slug":"pharvaris","ticker":"PHVS","exchange":"NASDAQ","domain":"pharvaris.com","description":"Pharvaris is a rare disease biotech company focused on developing treatments for hereditary angioedema (HAE). The company's top drugs include PHA-533132, a bradykinin receptor antagonist. Pharvaris is positioned to capitalize on the growing demand for HAE treatments.","hq":"Leiden, Netherlands","founded":0,"employees":"","ceo":"Berndt Modig","sector":"Rare Disease Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$1.1B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"PHA-533132 patent cliff ($0.0B at risk)","drug":"PHA-533132","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Deucrictibant high dose","genericName":"Deucrictibant high dose","slug":"deucrictibant-high-dose","indication":"Hypertension","status":"phase_2"}]}],"pipeline":[{"name":"Deucrictibant high dose","genericName":"Deucrictibant high dose","slug":"deucrictibant-high-dose","phase":"phase_2","mechanism":"Deucrictibant is a bradykinin receptor 2 antagonist.","indications":["Hypertension"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Pharvaris Announces FDA Fast Track Designation for PHA-533132","summary":"Pharvaris received FDA Fast Track designation for PHA-533132, a bradykinin receptor antagonist for the treatment of hereditary angioedema.","drugName":"PHA-533132","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Pharvaris Reports Third Quarter 2023 Financial Results","summary":"Pharvaris reported its third quarter 2023 financial results, with a net loss of $24.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-31","type":"deal","headline":"Pharvaris Announces Collaboration with HAEi to Advance HAE Research","summary":"Pharvaris partnered with HAEi to advance research in hereditary angioedema.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-07","type":"earnings","source":"simplywall.st","summary":"Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates - simplywall.st","headline":"Assessing Pharvaris (PHVS) Valuation After 2025 Earnings Loss And Deucrictibant Milestone Updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"pipeline","source":"simplywall.st","summary":"Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns - simplywall.st","headline":"Assessing Pharvaris (PHVS) Valuation After Recent Share Price Pullback And Strong Longer Term Returns","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-22","type":"pipeline","source":"simplywall.st","summary":"Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge? - simplywall.st","headline":"Is It Too Late To Consider Pharvaris (PHVS) After A 3.5x Three Year Surge?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQN2pCWDdhRENyTFpPQzU5XzFOYW1hRnY2NktsRndfMkx2TFUtYXVCV29FRWRwVnNmTXNTMF9la3RDb1R3UGdNaUhNc2RWbi1xSHhodWNVRmRQdmRKRzdycmFFTzZEeWhHRVNuYlFpTGF0Q285MzltdVVmNm1rSmZYM0wzRHg0UlFDRUs1SmVRMF9INlIxQ3B1NGZ0NWZtUkpj?oc=5","date":"2025-12-05","type":"pipeline","source":"Investor's Business Daily","summary":"Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily","headline":"Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNT0xUTVFPWDZRMmFBekpnaTBXN1FvV3cwSzVQcWdqZUIzZVJmaExyeWxmQWU5Y29PcDA2TmM5OFFEWGhXX2Z4dW9HVmVUeWdLRjB1V2xVc2hHQXdtSlJGOXN3blF4TnRNYlk0NDl5X2txVzRtbFlxVzNnYTE1NS15UTBB?oc=5","date":"2025-12-04","type":"trial","source":"Yahoo Finance","summary":"Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals - Yahoo Finance","headline":"Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNTnVHUFlhRVNVMVZySlk4Wi1KNjlwend5VFpmYVl1RGg2b2R6dm1WWm0tM2tBaHFsaXZ6bmJQbFBxdzUtWGdRR3FmeGpzUUdPcnh2TjRndzVjTXVsTzFZZzhhTmlzZGNBcFo2YV9WLTRlb2pRWjFvRmVNaXlwUm9QdA?oc=5","date":"2025-12-03","type":"pipeline","source":"Investor's Business Daily","summary":"Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily","headline":"Biotechs Duke It Out In A Genetic Disease — And Both Surge - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwJBVV95cUxPTTdwY3dBdDQ5ZnBTUTdZcWV2NkRCZzRsc1BjZ3J3Nmd4LWI3RXhaUnB4cDFfbEI3blZfTHBBTkRDR0pZcjZ3N2Jna2oxYnExUWc1YmdnekpwYlc0Vm1xSDIzY1h5ZUVwRlRSOXBoWFg2X2pvN09uZFdvSnNfTWJMdEtzaGVScUprZGZoR2M3RGNWa1I1eV9Qc0Q5dU5Gb3NKd3pMWGR2cmNoZWxMempKTlhtZHZiYVRaMjRqOHV4eWhlN2xPR2tBZ192b1FxODF0VUllM3lPWnFOeGtubWdXUWFvMVVUSnp3a0pvSG5pSFRWTmlWdnBYZTROSFMwZkhWRVdpWUZGYVlua1o5QjFhLWk1MnA5bDNkVE82dmNub1BLeDByNVZZbmlldnRFYWtpVmhSdXpTNU9wVkFaaUQ0?oc=5","date":"2025-12-03","type":"trial","source":"GlobeNewswire","summary":"Pharvaris Announces Positive Topline Data from RAPIDe-3 - GlobeNewswire","headline":"Pharvaris Announces Positive Topline Data from RAPIDe-3","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxQQ1hJcWt6cHVFaEVGM01LNVRsYXU3ajVtM3BvTzg0NkVJVU9RVm5mZ2FKMFBQNGhGSk1aelpQVVhvb2xOdXY0SjRpYTYtZi0tZUszTG9sMllrLWhKSkpWYjg3djZFcnlvbzREY2NObWRnSFBCTUxzYURnLXJJbHJFbjJaWWtWQTRwdXBFcE1NMDVfVXJVMEZtSkQzS2Z0X2dpTEV0bERHcExQcmFZeGVmaEVNYV9wM2puaFY5V0tPNVJGZDdoMjZyV1c1ZTVHUVFPeVo3U1VqYl9aTTA?oc=5","date":"2025-12-03","type":"pipeline","source":"Benzinga","summary":"Why Pharvaris Stock Is Soaring Today - Pharvaris (NASDAQ:PHVS) - Benzinga","headline":"Why Pharvaris Stock Is Soaring Today - Pharvaris (NASDAQ:PHVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNREU4XzR0dnJaVGlRTTZiR2FqVmE3R1A2RlUtWGdrQXc2QllIbEJPYlhmUmVLWnJyMml5cERPbmZ6b19xcHp2eWNOb1dsODRUaUJSMGhDR1RJNG0tRzFCOTAwU2k5OUFPdGJOXzJMdVFGclBxR2dhOFlDMVF2akU3N0JvSWlyWUNhQ2tZbWlicmUzTlFzX1RqR3Nsa2lIUDg?oc=5","date":"2025-12-03","type":"trial","source":"The Pharma Letter","summary":"Pharvaris rises on positive deucrictibant data in HAE - The Pharma Letter","headline":"Pharvaris rises on positive deucrictibant data in HAE","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxORnExcjZuNW1Fb0dhamFCd19hTGcxZ1Fna0VXb01OcWpsQlNKbDRxUllxelZHVUY3MWNKekZidkFBUXpSOFJ6UGhFeXZyNkNrS2VNbkQxU2RhV2IzZXViQ0sxRXAxZTM2SzIyRWFoYkZWZ3BYZlZvcFhnUUdjZG9IMGU2TmJFZFdHRG1jekllYWlicWlsSE45NHBxbXFtUQ?oc=5","date":"2025-07-23","type":"pipeline","source":"The Pharma Letter","summary":"Pharvaris secures $175 million public offering - The Pharma Letter","headline":"Pharvaris secures $175 million public offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE0tRVNTQlVwWmNYSWxuSHZwSkJOT2s1QXBsX3dscW5Vby1xdEtzWkl6MXZKeW1ibnFBMGMzTGVPTnlrakxvYlJUYmNFaXg3cWpTTUVIeV9jWi0ySnV2QkhJ?oc=5","date":"2021-10-26","type":"pipeline","source":"ChartMill","summary":"PHVS Stock Price, Quote & Chart | PHARVARIS NV (NASDAQ:PHVS) - ChartMill","headline":"PHVS Stock Price, Quote & Chart | PHARVARIS NV (NASDAQ:PHVS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPX0x3UXJWWENOeWZZOUVpSnFISk1jZUtnLXV2NG9HeTFieVd6X09NWlp3SGdBY1lBTFBEbjAwZlhKRkM5OEJ3TzIxVDBQRGZnUEZvbzJqVlV0eDU0VjdtRlFhUzBtTThCRE1ZVFdlM3QwZDFvMVlOb05kMGF1dXl4UA?oc=5","date":"2021-02-06","type":"pipeline","source":"MarketBeat","summary":"Top Pharvaris (PHVS) Competitors 2026 - MarketBeat","headline":"Top Pharvaris (PHVS) Competitors 2026","sentiment":"neutral"}],"patents":[{"drugName":"PHA-533132","drugSlug":"bradykinin-receptor-antagonist","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioCryst Pharmaceuticals","Ipsen","Takeda Pharmaceutical"],"therapeuticFocus":["Hereditary Angioedema"],"financials":null,"yahoo":null}